Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Cormorant Pharmaceuticals AB
AB
Active
Org 5568213853
Solnavägen 3 H, 113 63
Stockholm
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2010 · 15 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Cormorant Pharmaceuticals AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
0M
-1M
-1M
2020: 0M
0M
2020
2021: 0M
0M
2021
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
EBITDA
SEK millions
1.5B
1.0B
0.6B
0.1B
-0.4B
2020: 1.1B
1.1B
2020
2021: -0.0B (-101% vs 2020)
-0.0B
-101%
2021
2022: 0B (+100% vs 2021)
0B
+100%
2022
2023: 0B
0B
2023
2024: -0.0B
-0.0B
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
0
0
0
0
0
Staff expenses
—
—
—
—
—
EBITDA
−786
−438
−497
−8 334
1 143 231
Depreciation & amort.
−0
−0
−0
−0
−0
EBIT
−786
−438
−497
−8 334
1 143 231
Net financials
1 312
1 839
420
4 684
15 109
Profit before tax
525
1 401
−77
−3 651
1 158 340
Tax
−95
−200
−298
−0
−244 792
Net profit
430
1 201
−375
−3 651
913 548
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
10 060
56 123
54 571
299 093
1 156 854
Equity
9 502
55 692
54 117
53 904
922 669
Long-term debt
0
0
0
0
0
Short-term debt
557
431
454
245 188
234 185
Total debt
557
431
454
245 188
234 185
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2020
2024
Equity ratio
94,5 %
This company
38,2 %
Market median
This company
Market median
147% above market
2020
2024
Return on equity
4,5 %
This company
18,4 %
Market median
This company
Market median
76% below market
2020
2024
Net profit margin
>999 %
This company
8,1 %
Market median
This company
Market median
>999% above market
2020
2024
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2020
2024
Debt / equity
0,06×
This company
0,62×
Market median
This company
Market median
90% below market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Cormorant Pharmaceuticals AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
